{"id":18334,"date":"2021-06-16T08:00:28","date_gmt":"2021-06-16T12:00:28","guid":{"rendered":"https:\/\/medicarereport.org\/?p=18334"},"modified":"2021-06-16T08:00:28","modified_gmt":"2021-06-16T12:00:28","slug":"qa-the-ceo-of-the-alzheimers-association-on-the-approval-of-aduhelm-and-why-critics-should-stop-dwelling-on-the-decision","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=18334","title":{"rendered":"Q&#038;A: The CEO of the Alzheimer\u2019s Association on the approval of Aduhelm \u2014 and why critics should stop dwelling on the decision"},"content":{"rendered":"<p>(By Andrew Joseph for ST<em>A<\/em>T)<\/p>\n<p>Harry Johns is ready to stop talking about whether or not the Food and Drug Administration should have approved Aduhelm, the divisive new Alzheimer\u2019s treatment that got the green light last week.\u00a0 Continue reading the article <a href=\"https:\/\/www.statnews.com\/2021\/06\/16\/qa-ceo-alzheimers-association-on-aduhelm\/\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Andrew Joseph for STAT) Harry Johns is ready to stop talking about whether or not the Food and Drug<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,31,15],"tags":[],"class_list":["post-18334","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-fda","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18334"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18334\/revisions"}],"predecessor-version":[{"id":18335,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18334\/revisions\/18335"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}